Understanding the Market | ASCLETIS-B rises over 5% as ASC30 demonstrates superior efficacy and safety data; the company has many catalysts in the second half of the year
I'm PortAI, I can summarize articles.
ASCLETIS-B's stock price rose by more than 5%, with an increase of 5.02% as of the time of publication, reported at HKD 10.88, with a trading volume of HKD 92.5898 million. The company reported the clinical research results of ASC30 at the upcoming European Association for the Study of Diabetes annual meeting, showing superior performance in weight loss and safety. Soochow Securities pointed out that the company has several important clinical data set to be disclosed in the second half of the year and is expected to submit multiple new pipeline INDs to the FDA
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments